Individual mutation profiles as guideline
The CPCT uses ‘Next Generation Sequencing’ (NGS) technology, situated in the facilities of the Hartwig Medical Foundation (see Research techniques), to map genetic changes in cancer. Mutations in the genome are the basis for every type of cancer and disrupt essential processes in the tumor. There are targeted therapies focused on specific disrupted processes based on genetic defects. This allows tumor growth to be stopped with fewer side effects than ‘traditional’ chemotherapy. Identifying genetic defects is therefore an important new step in cancer treatment as it enables us to develop new medication. Moreover, it allows the more targeted use of existing drugs that focus on specific defects in the tumor of an individual patient.